The Food and Drug Administration warned that taking anti-malaria drug hydroxychloroquine along with antiviral drug remdesivir 'may result in reduced antiviral activity' of the latter.
The Food and Drug Administration warned Monday that taking anti-malaria drug hydroxychloroquine along with antiviral drug remdesivir "may result in reduced antiviral activity" of the latter.
A recently completed non-clinical study discovered the potential drug interaction, the agency said in its notice published Monday evening. A pharmacy tech holds a bottle and a pill of Hydroxychloroquine at Rock Canyon Pharmacy in Provo, Utah, on May 20, 2020.The Food and Drug Administration warned Monday that Covid-19 patients taking anti-malaria drug hydroxychloroquine along with antiviral drug remdesivir may weaken the effectiveness of the latter.
The FDA is revising its fact sheet for health-care providers that accompanies remdesivir to state "that co-administration of remdesivir and chloroquine phosphate or hydroxychloroquine sulfate is not recommended as it may result in reduced antiviral activity of remdesivir."agency said in its notice"The agency is not aware of instances of this reduced activity occurring in the clinical setting but is continuing to evaluate all data related to remdesivir," the FDA wrote.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
FDA revokes authorization of drug Trump toutedThe FDA has determined that the drugs hydroxychloroquine and chloroquine do not meet 'the statutory criteria' for emergency use authorization as they are unlikely to be effective in treating Covid-19 based on the latest scientific evidence
続きを読む »
FDA revokes permission to treat COVID-19 with hydroxychloroquine, drug previously touted by TrumpThe FDA says it has revoked emergency authorization for hydroxychloroquine and chloroquine to treat COVID-19, saying the evidence shows the recommended dose is unlikely to be effective against the virus.
続きを読む »